Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Immunotherapy
|
October 25, 2017
Rituximab in pemphigus
Vivien Hebert, Pascal Joly
JAAD Case Reports
|
January 24, 2019
Linear IgA bullous dermatosis treated with rituximab
Camille Pinard, Vivien Hebert, Myriam Lecuyer, et al.
JAAD Case Reports
|
September 30, 2020
Severe dapsone-induced hypoalbuminemia in a case of mucous membrane pemphigoid
Jasmine Flament, Lamia Jelti, Catherine Lok, et al.
JAAD Case Reports
|
June 27, 2022
Botryoid connective tissue nevi: An uncommon presentation of hamartoma of the skin
Emma Huard, Margot Raynal, Sylvie Fraitag, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
October 5, 2019
Senegal, a new potential endemic country for Buruli ulcer?
Lucie Dupechez, Priscille Carvalho, Vivien Hebert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 9, 2024
Efficacy of virtual reality on pain and anxiety management in dermatological procedures
Jeanne Guillet, Billal Tedbirt, Vivien Hebert, et al.
Journal of the American Academy of Dermatology
|
February 19, 2017
Sensitivity and specificity of BP180 NC16A enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis
Fatimah Al Saif, Fabienne Jouen, Vivien Hebert, et al.
JID Innovations : Skin Science From Molecules to Population Health
|
July 21, 2022
How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey
Marine Guignant, Billal Tedbirt, Dedee F Murrell, et al.
The Journal of Investigative Dermatology
|
December 14, 2018
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population
Marthe Plaquevent, Florence Tétart, Laurence Fardet, et al.
Lancet (London, England)
|
March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
Pascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Immunotherapy
|
October 25, 2017
Rituximab in pemphigus
Vivien Hebert, Pascal Joly
JAAD Case Reports
|
January 24, 2019
Linear IgA bullous dermatosis treated with rituximab
Camille Pinard, Vivien Hebert, Myriam Lecuyer, et al.
JAAD Case Reports
|
September 30, 2020
Severe dapsone-induced hypoalbuminemia in a case of mucous membrane pemphigoid
Jasmine Flament, Lamia Jelti, Catherine Lok, et al.
JAAD Case Reports
|
June 27, 2022
Botryoid connective tissue nevi: An uncommon presentation of hamartoma of the skin
Emma Huard, Margot Raynal, Sylvie Fraitag, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
October 5, 2019
Senegal, a new potential endemic country for Buruli ulcer?
Lucie Dupechez, Priscille Carvalho, Vivien Hebert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 9, 2024
Efficacy of virtual reality on pain and anxiety management in dermatological procedures
Jeanne Guillet, Billal Tedbirt, Vivien Hebert, et al.
Journal of the American Academy of Dermatology
|
February 19, 2017
Sensitivity and specificity of BP180 NC16A enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis
Fatimah Al Saif, Fabienne Jouen, Vivien Hebert, et al.
JID Innovations : Skin Science From Molecules to Population Health
|
July 21, 2022
How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey
Marine Guignant, Billal Tedbirt, Dedee F Murrell, et al.
The Journal of Investigative Dermatology
|
December 14, 2018
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population
Marthe Plaquevent, Florence Tétart, Laurence Fardet, et al.
Lancet (London, England)
|
March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
Pascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
Page
of 1